Hui Cao

Hui Cao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SSShuping Si
Shuping Si
LWLei Wang
Lei Wang
HCHui Cao
Hui Cao
YXYuhua Xu
Yuhua Xu
QZQiang Zhan
Qiang Zhan
Background: Immunotherapy is a novel hotspot for the treatment of pancreatic adenocarcinoma (PAAD). However, potential biomarkers which could identify the inflamed tumor microenvironment (TME) are urgently required. Methods: In the present study, we measured the levels of B7-H3, B7-H4, and major tumor-infiltrating immune cells (TIICs) using bioinformatics analyses and immunohistochemistry (IHC) staining on PAAD samples represented in the tissue microarray (TMA) format. Statistical analysis and figures exhibition were performed using R 4.1.0, SPSS 26.0, and GraphPad Prism 6.0. Results: B7-H3 and B7-H4 were up-regulated in PAAD compared with para-tumor tissues, and their expression exhibited no tight correlation in PAAD tissues. B7-H3 and B7-H4 were lowly expressed in well-differentiated PAAD tissues and correlated with poorly differentiated grades. Besides, single B7-H3 or B7-H4 expression exhibited limited prognostic value, but co-deficiency of B7-H3 and B7-H4 predicted a better prognosis in PAAD. Moreover, co-deficiency of B7-H3 and B7-H4 indicated immuno-hot tumors with high CD8 + T cell infiltration. Conclusions: Overall, combined B7-H3 and B7-H4 expression is a promising stratification strategy to assess prognosis and immunogenicity in PAAD, which could be used as a novel classifier in clinical practice.

25 November 2025 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
BXBingxin Xu
Bingxin Xu
CYCheng Yang
Cheng Yang
LJLin Ji
Lin Ji
ZXZhenxiong Xie
Zhenxiong Xie
HCHui Cao
Hui Cao